T-DXd Effective for Treating HER2+ Advanced or Metastatic Breast Cancer, Regardless of Treatment History, HR Status, or PIK3C Mutations - report from ESMO 2025

Professor Sibylle Loibl shares her thoughts on the additional analyses of DESTINY-Breast09 were presented at the ESMO Congress 2025. Key subgroup analysis of DESTINY-Breast09 confirms efficacy of trastuzumab deruxtecan plus pertuzumab for treating HER2+ advanced or metastatic breast cancer across groups.

Video: https://medicaldigest.org/scientific-contents/interview:t-dxd-effective-treating-her2-advanced-or-metastatic-breast-cancer-regardless-treatment-history-hr-status-or-pik3c-mutations